What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects in the APC-0101 group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface and APC-0101 treatment will be started.”In the company’s words, NCT06776783 on ClinicalTrials.gov
- Tested for
- Respiratory Distress Syndrome, Pre-term Infants
- Main trialPhase 3
- “This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.”In the company’s words, NCT06776783 on ClinicalTrials.gov
Other drugs for Respiratory Distress Syndrome
- TozorakimabAstraZeneca · Phase 3
- ExoFloDirect Biologics, LLC · Phase 3
- Aerosolized CalfactantONY · Phase 3
- LEAF-4L6715LEAF4Life, Inc. · Phase 3
- STSA-1002Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3
- SecretomePT. Prodia Stem Cell Indonesia · Phase 1/2
Coming up1
- May 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2027 | Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026